Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
In research studies, lenalidomide (also called Revlimid) has shown some response in chronic
lymphocytic leukemia (CLL); however, responses are usually partial responses that occur after
several months of taking the study drug. It is thought that by adding the drug plerixafor
(also called Mozobil) responses may be improved and/or occur sooner.
The main purpose of this study is to determine the dose of plerixafor that is safe to use in
combination with lenalidomide. The study will also look at the response rates of the
combination of lenalidomide and plerixafor and the effect the study drugs have on CLL cells.
Phase:
Phase 1
Details
Lead Sponsor:
David Rizzieri, MD
Collaborators:
Celgene Corporation Genzyme, a Sanofi Company
Treatments:
JM 3100 Lenalidomide Plerixafor Rituximab Thalidomide